OncLive TV

Brian A. Van Tine, MD, PhD, discussed trial findings with olaparib plus temozolomide in advanced uterine leiomyosarcoma following prior chemotherapy.

Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.

Elena Élez, MD, PhD, discusses health-related QOL data with nivolumab plus ipilimumab in mCRC.

David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Shahzad Raza, MD, highlights the challenges associated with managing relapsed/refractory multiple myeloma with extramedullary disease.

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

Waddah Arafat, MD, discusses ​how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

Cyrus M. Khan, MD, detailed the development of second-generation BTK inhibitors and how they compare with first-generation BTK inhibitors in CLL.

R. Lor Randall, MD, FACS, discusses the management of non-ossifying fibromas, and how this differs from that of malignant tumors.

Neelam Desai, MD, discusses the current body of evidence for CDK 4/6 inhibitor use in metastatic HR-positive, HER2-negative breast cancer.

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Julie M. Vose, MD, MBA, details the rationale for evaluating epcoritamab for the treatment of patients with relapsed/refractory DLBCL with limited options.

Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.

Andrea Necchi, MD, discusses biomarker data with perioperative sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible MIBC.

Qian (Janie) Qin, MD, discusses the unique design of the phase 2 HARMONY trial of ​first-line niraparib plus abiraterone acetate and prednisone in mHSPC.

Meletios A. Dimopoulos, MD, discusses the efficacy of BVd vs DVd in patients with relapsed or refractory multiple myeloma.

Joseph Vento, MD, discusses the importance of using somatic NGS to guide treatment decision-making for patients with non–clear cell RCC.

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and manageable safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Paul Nathan, MBBS, PhD, MRCP, details the rationale for evaluating roginolisib in patients with advanced or metastatic ocular or uveal melanoma.

Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Jens Bedke, MD, discusses considerations for using enfortumab vedotin plus pembrolizumab in the frontline setting for advanced urothelial carcinoma.

Jessica Paulus, ScD, discusses the development of a real-world control arm to inform the utility of findings from a trial in HER2-positive breast cancer.

Alberto Farolfi, MD, PhD, discusses real-world findings with bevacizumab plus platinum-based chemotherapy and pembrolizumab in advanced cervical cancer.

Deba Sarma, MD, highlights the role of sentinel node biopsies ahead of surgery for the treatment of patients with breast cancer.